Home Infusion Therapy Market Size, Growth Rate and Forecast to 2034: Drivers, Risks and Regional Outlook
Home infusion therapy is forecast to reach USD 82.96 billion by 2034 at an 8% CAGR; this analysis covers the size, the driver, the bear case and where growth sits.
Home infusion moves intravenous and other infused treatments out of the hospital and into the patient's house. The forecast for the home infusion therapy market runs from a 2025 base to 2034, with 2020 to 2024 as the historical period. This article sets out the size, the growth rate, what carries it and what could pull it down.
Market size and growth rate
The market was USD 41.5 billion in 2025. The forecast takes it to USD 82.96 billion in 2034 at a CAGR of 8%.
The history gives the forecast something to stand on. Revenue was USD 28.9 billion in 2020 and USD 39 billion in 2024, a compound rate of 7.51% across the historical period. The forecast carries 8% from there, applied flat across 2026 to 2034 and not ramped.
The series shows fifteen years of unbroken growth. That makes the forecast an extension of a demonstrated trajectory. It does not depend on a projected turnaround.
Two alternative paths bracket the base case. The upside case reaches USD 91.92 billion by 2034. The bear case reaches USD 74 billion. Both start from the same USD 41.5 billion base in 2025, so the disagreement is entirely about the rate of growth after it.
A reader sizing a related service line may also want the home infusion therapy services market, which is scoped separately by device type, application and component. Its headline is USD 91.1 billion by 2034 at a CAGR of 9.04%. The two reports define their markets differently, so their totals should not be set against each other as like for like.
What is driving it
One line on the therapy type axis carries the market's growth rate. Specialty Biologics and Rare Disease Therapies grows at 12.75% against 8% for the market. It takes USD 4.98 billion in 2025 to USD 14.81 billion in 2034, and its share of revenue goes from 12% to 17.85%.
Nothing else on the axis grows as fast. Hydration Therapy, the next line cited in the data, manages 5.44%. The blended 8% is therefore a weighted result, and one therapy line is doing most of the lifting. A portfolio weighted away from specialty biologics will track below the market even when the market grows in every segment.
The upside case names the conditions that would push growth higher:
- faster transfer of care from hospitals to the home
- wider payer coverage for home infusion drugs
- quicker uptake of subcutaneous biologics
The third of these links back to the same specialty biologics line. Subcutaneous routes are one of the five route-of-administration segments the report tracks, alongside intravenous, enteral, epidural and intrathecal, and intramuscular.
Telehealth sits next to this market in the care pathway. Remote patient monitoring and telepharmacy are a service type segment inside home infusion itself, and the wider remote-care market is covered in the telemedicine market, which has a CAGR of 17% to USD 572.35 billion by 2034.
What could slow it
The bear case is the clearest statement of risk. It reaches USD 74 billion in 2034 against USD 82.96 billion in the base case. It rests on one stated assumption: slower coverage expansion, nursing shortages and tighter payer controls on infusion drugs hold growth below the base path. Neither case changes the USD 41.5 billion 2025 base.
A second restraint sits inside the segment mix. Anti-Infective Therapy carries 26.99% of 2025 revenue, USD 11.2 billion. It compounds at 6.73% against 8% for the market. Its share falls to 24.3% by 2034 even as its revenue rises to USD 20.16 billion.
Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it. The concentration also means the market's forecast is, to a large extent, a forecast for one therapy type line.
The restraints in the data are about access and delivery, and they interact. Payer controls limit what is reimbursed at home. Nursing shortages limit how much can be delivered there. Either one can cap growth without the other moving.
Where the growth sits
By therapy type, the shares of 2025 revenue are:
- Anti-Infective Therapy: 26.99%
- Parenteral Nutrition: 14%
- Enteral Nutrition: 6%
- Immunoglobulin Therapy: 12%
- Chemotherapy: 10%
- Pain Management: 7.01%
- Hydration Therapy: 6.99%
- Inotropic and Cardiac Therapy: 5.01%
- Specialty Biologics and Rare Disease Therapies: 12%
Anti-Infective Therapy is the largest line. Specialty Biologics and Rare Disease Therapies has the same 12% share as Immunoglobulin Therapy in 2025 but is the fastest by a wide margin, which is where share changes hands at scale. An entrant can take position there without displacing the incumbent in anti-infectives.
The report covers five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The geographic point the data makes most clearly concerns concentration inside North America. The United States generates USD 20.3 billion of the region's USD 21.58 billion in 2025, which is 94.1% of the region. It reaches USD 36.9 billion by 2034.
A regional figure that depends this heavily on one country carries that country's specific conditions inside it. Payer rules, reimbursement and staffing in the United States shape the North American number almost entirely. A reader who treats the region as diversified would miss that.
The segmentation goes well beyond therapy type. The report also splits the market by product, service type, route of administration, indication, provider type, patient age group, payer type, care setting and duration of therapy. For readers who want to see how adjacent service categories are sized, the behavioral health market is another Healthcare Services report on the site, with a CAGR of 6.52% to USD 324 billion by 2034.
The full segment tables and country detail are in the report itself.
More in this cluster
- Healthcare Services
Behavioral Health Market Size, Growth Rate and Forecast to 2034: Drivers, Risks and Regional Analysis
- Healthcare Services
Telemedicine Market: Size, Growth Driver, and Where Revenue Concentrates Through 2034
- Agriculture
Green Fertilizer Market Size, Growth Rate and Forecast to 2034: Drivers, Risks and Regional Split